ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
23 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Group PLC US Supply Agreement (6226T)

16/10/2017 7:00am

UK Regulatory


Omega Diagnostics (LSE:ODX)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Omega Diagnostics Charts.

TIDMODX

RNS Number : 6226T

Omega Diagnostics Group PLC

16 October 2017

Omega Diagnostics Group PLC

("Omega" or the "Company")

US Supply Agreement

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has signed a Supply Agreement with a US-based company offering laboratory testing services, specialising in gut health for improved health outcomes.

The agreement, which covers Omega's microarray-based food intolerance product FoodPrint(R), is for an initial term of three years and is automatically renewable thereafter on the mutual agreement of both parties. This agreement will enable the Company to increase traction in the US for FoodPrint(R) which provides laboratories with a high throughput food sensitivity testing solution. Omega expects a modest contribution from this arrangement in the current financial year.

The global market for Food Allergy and Intolerance products is projected to exceed $24.8 billion by 2020, driven by the rise in food hypersensitivity, allergies and associated anaphylaxis as a result of changes in diet and sensitivity to food additives and increased use of sulphur dioxide and sulphites as preservatives. The United States represents the largest market worldwide, led by the ongoing trend of selective food avoidance among the affluent health conscious consumers. (Source: http://www.strategyr.com/pressMCP-6441.asp)

Andrew Shepherd, Chief Executive Officer of Omega, commented: "We are pleased to have signed this agreement that enables us to broaden our food intolerance product offering in the important US market. We are excited by the prospects for this relationship and believe the capabilities of our chosen partner will enable us to deliver better health outcomes for patients."

Contacts:

 
 Omega Diagnostics Group PLC                                     Tel: 01259 763 030 
 Andrew Shepherd, Chief Executive                          www.omegadiagnostics.com 
 Kieron Harbinson, Group Finance 
  Director 
 Jag Grewal, Group Sales and Marketing 
  Director 
 
 finnCap Ltd                                                     Tel: 020 7220 0500 
 Geoff Nash/James Thompson (Corporate 
  Finance) 
 Mia Gardner (Corporate Broking) 
 
 Walbrook PR Limited                     Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                    Mob: 07980 541 893 
 Lianne Cawthorne                                                Mob: 07584 391 303 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGREAPESFEEXFEF

(END) Dow Jones Newswires

October 16, 2017 02:00 ET (06:00 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Your Recent History

Delayed Upgrade Clock